Smart Equipment & Technology Selection: De-risks Your Monoclonal Antibody Scale-Up Process

By Timothy Korwan, Director – Technical Applications

Manufacturers are scaling up their monoclonal antibody (mAb) processes to meet a rising market demand. The time frame for mAbs, from research and development to commercialization, is thought to take a decade or more. Any delays during the clinical trial phase can cause significant additional costs. Innovations in raw materials, equipment and single-use technology continue to improve to help ;avoid obstacles and maximize efficiency.

Adopting a technology platform approach using a fluid handling system that can transition from development to your final production volume will ensure a smoother technology transfer and increased confidence in your process.